Form 8-K - Current report:
SEC Accession No. 0001213900-25-034254
Filing Date
2025-04-22
Accepted
2025-04-22 17:10:19
Documents
15
Period of Report
2025-04-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0239156-8k_denali.htm   iXBRL 8-K 45189
2 AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER, DATED AS OF APRIL 16, 2025, BY ea023915601ex2-1denali.htm EX-2.1 27259
  Complete submission text file 0001213900-25-034254.txt   309841

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE deca-20250416.xsd EX-101.SCH 4172
4 XBRL DEFINITION FILE deca-20250416_def.xml EX-101.DEF 27297
5 XBRL LABEL FILE deca-20250416_lab.xml EX-101.LAB 37878
6 XBRL PRESENTATION FILE deca-20250416_pre.xml EX-101.PRE 25917
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0239156-8k_denali_htm.xml XML 6840
Mailing Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022
Business Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022 6469785180
Denali Capital Acquisition Corp. (Filer) CIK: 0001913577 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41351 | Film No.: 25858487
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)